The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Alliance with EPR Effect: Combined Strategies to Improve the EPR Effect in the Tumor Microenvironment
Open accessAbstract
The use of nanomedicine for cancer treatment takes advantage of its preferential accumulation in tumors owing to the enhanced permeability and retention (EPR) effect. The development of cancer nanomedicine has promised highly effective treatment options unprecedented by standard therapeutics. However, the therapeutic efficacy of passively targeted nanomedicine is not always satisfactory because it is largely influenced by the heterogeneity of the intensity of the EPR effect exhibited within a tumor, at different stages of a tumor, and among individual tumors. In addition, limited data on EPR effectiveness in human hinders further clinical translation of nanomedicine. This unsatisfactory therapeutic outcome in mice and humans necessitates novel approaches to improve the EPR effect. This review focuses on current attempts at overcoming the limitations of traditional EPR-dependent nanomedicine by incorporating supplementary strategies, such as additional molecular targeting, physical alteration, or physiological remodeling of the tumor microenvironment. This review will provide valuable insight to researchers who seek to overcome the limitations of relying on the EPR effect alone in cancer nanomedicine and go "beyond the EPR effect".
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Nano based drug delivery systems: recent developments and future prospects
Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V. R., Rodriguez-Torres, M. D. P., Acosta-Torres, L. S., Diaz-Torres, L. A., Grillo, R., Swamy, M. K., Sharma, S., et al. (2018) · Journal of Nanobiotechnology · doi:10.1186/s12951-018-0392-8 · Cited by 6,684
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J., & Corrie, S. R. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1958-5 · Cited by 2,586
The Tumour Microenvironment after Radiotherapy: Mechanisms of Resistance and Recurrence
Barker, H. E., Paget, J. T. E., Khan, A. A., & Harrington, K. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3958 · Cited by 2,144 · cited 1×
“Recently, advances in nanotechnology utilizing the EPR effect have enabled novel strategies for nanomedicine treatment in combination with RT [90].”
BackgroundHIF-1α pathway: role, regulation and intervention for cancer therapy
Masoud, G. N., & Li, W. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.05.007 · Cited by 1,871
Emerging functions of the EGFR in cancer
Sigismund, S., Avanzato, D., & Lanzetti, L. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12155 · Cited by 1,469
Acidity Generated by the Tumor Microenvironment Drives Local Invasion
Estrella, V., Chen, T., Lloyd, M., Wojtkowiak, J., Cornnell, H. H., Ibrahim-Hashim, A., Bailey, K., Balagurunathan, Y., Rothberg, J. M., Sloane, B. F., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2796 · Cited by 1,397
Acidic extracellular microenvironment and cancer
Kato, Y., Ozawa, S., Miyamoto, C., Maehata, Y., Suzuki, A., Maeda, T., & Baba, Y. (2013) · Cancer Cell International · doi:10.1186/1475-2867-13-89 · Cited by 1,300
Tumor targeting via EPR: Strategies to enhance patient responses
Golombek, S. K., May, J.-N., Theek, B., Appold, L., Drude, N., Kiessling, F., & Lammers, T. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.007 · Cited by 1,262
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective
Hare, J. I., Lammers, T., Ashford, M. B., Puri, S., Storm, G., & Barry, S. T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.025 · Cited by 1,214
Rethinking cancer nanotheranostics
Chen, H., Zhang, W., Zhu, G., Xie, J., & Chen, X. (2017) · Nature Reviews Materials · doi:10.1038/natrevmats.2017.24 · Cited by 1,102
The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages.
Allavena, P., Sica, A., Solinas, G., Porta, C., & Mantovani, A. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.07.004 · Cited by 1,044
Chauhan, V. P., Martin, J. D., Liu, H., Lacorre, D. A., Jain, S. R., Kozin, S. V., Stylianopoulos, T., Mousa, A. S., Han, X., Adstamongkonkul, P., et al. (2013) · Nature Communications · doi:10.1038/ncomms3516 · Cited by 1,031
Dai, Y., Xu, C., Sun, X., & Chen, X. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00592f · Cited by 931
Disrupting tumour blood vessels
Tozer, G. M., Kanthou, C., & Baguley, B. C. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1628 · Cited by 930
Progress in Nanomedicine: Approved and Investigational Nanodrugs.
Ventola, C. L. (2017) · Europe PMC (PubMed Central) · Cited by 835
The expanding role of prodrugs in contemporary drug design and development
Rautio, J., Meanwell, N. A., Di, L., & Hageman, M. J. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.46 · Cited by 767
Toward understanding and exploiting tumor heterogeneity
Alizadeh, A. A., Aranda, V., Bardelli, A., Blanpain, C., Bock, C., Borowski, C., Caldas, C., Califano, A., Doherty, M., Elsner, M., et al. (2015) · Nature Medicine · doi:10.1038/nm.3915 · Cited by 746
αv Integrins as receptors for tumor targeting by circulating ligands
Pasqualini, R., Koivunen, E., & Ruoslahti, E. (1997) · Nature Biotechnology · doi:10.1038/nbt0697-542 · Cited by 744
Diop-Frimpong, B., Chauhan, V. P., Krane, S., Boucher, Y., & Jain, R. K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018892108 · Cited by 733
Vakoc, B. J., Lanning, R. M., Tyrrell, J. A., Padera, T. P., Bartlett, L. A., Stylianopoulos, T., Munn, L. L., Tearney, G. J., Fukumura, D., Jain, R. K., et al. (2009) · Nature Medicine · doi:10.1038/nm.1971 · Cited by 719
Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy
Min, Y., Roche, K. C., Tian, S., Eblan, M. J., McKinnon, K. P., Caster, J. M., Chai, S., Herring, L. E., Zhang, L., Zhang, T., et al. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.113 · Cited by 701
Defining the role of the tumor vasculature in antitumor immunity and immunotherapy
Schaaf, M. B., Garg, A. D., & Agostinis, P. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0061-0 · Cited by 629
Herceptin acts as an anti-angiogenic cocktail
Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D., & Jain, R. K. (2002) · Nature · doi:10.1038/416279b · Cited by 623
Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer
Welti, J., Loges, S., Dimmeler, S., & Carmeliet, P. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70212 · Cited by 591
Lakins, M. A., Ghorani, E., Munir, H., Martins, C. P., & Shields, J. D. (2018) · Nature Communications · doi:10.1038/s41467-018-03347-0 · Cited by 578
Vascular Targeting Agents as Cancer Therapeutics
Thorpe, P. E. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0642-03 · Cited by 577
Clinical management of breast cancer heterogeneity
Zardavas, D., Irrthum, A., Swanton, C., & Piccart, M. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.73 · Cited by 570
Facing the Truth about Nanotechnology in Drug Delivery
Park, K. (2013) · ACS Nano · doi:10.1021/nn404501g · Cited by 544
Light‐Activated Hypoxia‐Responsive Nanocarriers for Enhanced Anticancer Therapy
Qian, C., Yu, J., Chen, Y., Hu, Q., Xiao, X., Sun, W., Wang, C., Feng, P., Shen, Q., & Gu, Z. (2016) · Advanced Materials · doi:10.1002/adma.201505869 · Cited by 466
Magnetic Nanoparticles in Cancer Theranostics
Gobbo, O. L., Sjaastad, K., Radomski, M. W., Volkov, Y., & Prina-Mello, A. (2015) · Theranostics · doi:10.7150/thno.11544 · Cited by 462
Disulfide Bond-Driven Oxidation- and Reduction-Responsive Prodrug Nanoassemblies for Cancer Therapy
Sun, B., Luo, C., Yu, H., Zhang, X., Chen, Q., Yang, W., Wang, M., Kan, Q., Zhang, H., Wang, Y., et al. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b00737 · Cited by 426
Heterogeneity of the Tumor Vasculature
Nagy, J., Chang, S.-H., Shih, S.-C., Dvorak, A., & Dvorak, H. (2010) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0030-1253454 · Cited by 422
Kano, M. R., Bae, Y., Iwata, C., Morishita, Y., Yashiro, M., Oka, M., Fujii, T., Komuro, A., Kiyono, K., Kaminishi, M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611660104 · Cited by 410
Cancer drug delivery in the nano era: An overview and perspectives
Li, Z., Tan, S., Li, S., Shen, Q., & Wang, K. (2017) · Oncology Reports · doi:10.3892/or.2017.5718 · Cited by 406
Cell Plasticity and Heterogeneity in Cancer
Marjanovic, N. D., Weinberg, R. A., & Chaffer, C. L. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2012.184655 · Cited by 400
Overchuk, M., & Zheng, G. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2017.10.024 · Cited by 383
Alteration of the Antitumor Immune Response by Cancer-Associated Fibroblasts
Ziani, L., Chouaib, S., & Thiery, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00414 · Cited by 381
Kwon, S., Ko, H., You, D. G., Kataoka, K., & Park, J. H. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00136 · Cited by 370
Self-citationHypoxia-responsive polymeric nanoparticles for tumor-targeted drug delivery
Thambi, T., Deepagan, V. G., Yoon, H. Y., Han, H. S., Kim, S.-H., Son, S., Jo, D.-G., Ahn, C.-H., Suh, Y. D., Kim, K., et al. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.11.022 · Cited by 359
Self-citationPericyte-expressed Tie2 controls angiogenesis and vessel maturation
Teichert, M., Milde, L., Holm, A., Stanicek, L., Gengenbacher, N., Savant, S., Ruckdeschel, T., Hasanov, Z., Srivastava, K., Hu, J., et al. (2017) · Nature Communications · doi:10.1038/ncomms16106 · Cited by 348
Mechanisms and Barriers in Cancer Nanomedicine: Addressing Challenges, Looking for Solutions
Anchordoquy, T. J., Barenholz, Y., Boraschi, D., Chorny, M., Decuzzi, P., Dobrovolskaia, M. A., Farhangrazi, Z. S., Farrell, D., Gabizon, A., Ghandehari, H., et al. (2017) · ACS Nano · doi:10.1021/acsnano.6b08244 · Cited by 337
Self-citationEvolution of the nanoparticle corona
Hadjidemetriou, M., & Kostarelos, K. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.61 · Cited by 336
Clinical development of new drug–radiotherapy combinations
on behalf of the NCRI CTRad Academia-Pharma Joint Working Group, Sharma, R. A., Plummer, R., Stock, J. K., Greenhalgh, T. A., Ataman, O., Kelly, S., Clay, R., Adams, R. A., Baird, R. D., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.79 · Cited by 320
Choi, K. Y., Han, H. S., Lee, E. S., Shin, J. M., Almquist, B. D., Lee, D. S., & Park, J. H. (2019) · Advanced Materials · doi:10.1002/adma.201803549 · Cited by 319
Self-citationGao, R., Mei, X., Yan, D., Liang, R., & Wei, M. (2018) · Nature Communications · doi:10.1038/s41467-018-05223-3 · Cited by 307
Enzymatic Depletion of Tumor Hyaluronan Induces Antitumor Responses in Preclinical Animal Models
Thompson, C. B., Shepard, H. M., O'Connor, P. M., Kadhim, S., Jiang, P., Osgood, R. J., Bookbinder, L. H., Li, X., Sugarman, B. J., Connor, R. J., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0470 · Cited by 298
Belfiore, L., Saunders, D. N., Ranson, M., Thurecht, K. J., Storm, G., & Vine, K. L. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.02.040 · Cited by 294
Bioorthogonal Copper‐Free Click Chemistry In Vivo for Tumor‐Targeted Delivery of Nanoparticles
Koo, H., Lee, S., Na, J. H., Kim, S. H., Hahn, S. K., Choi, K., Kwon, I. C., Jeong, S. Y., & Kim, K. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201206703 · Cited by 293
Self-citationDings, R. P. M., Loren, M., Heun, H., McNiel, E., Griffioen, A. W., Mayo, K. H., & Griffin, R. J. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2441 · Cited by 286
Clinical Application of Radiolabeled RGD Peptides for PET Imaging of Integrin αvβ3
Chen, H., Niu, G., Wu, H., & Chen, X. (2016) · Theranostics · doi:10.7150/thno.13242 · Cited by 282
Surface design of magnetic nanoparticles for stimuli-responsive cancer imaging and therapy
Kang, T., Li, F., Baik, S., Shao, W., Ling, D., & Hyeon, T. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.05.013 · Cited by 280
Han, S.-S., Li, Z.-Y., Zhu, J.-Y., Han, K., Zeng, Z.-Y., Hong, W., Li, W.-X., Jia, H.-Z., Liu, Y., Zhuo, R.-X., et al. (2015) · Small · doi:10.1002/smll.201402865 · Cited by 269
Design of Nanoparticle-Based Carriers for Targeted Drug Delivery
Yu, X., Trase, I., Ren, M., Duval, K., Guo, X., & Chen, Z. (2016) · Journal of Nanomaterials · doi:10.1155/2016/1087250 · Cited by 265
Ojha, T., Pathak, V., Shi, Y., Hennink, W. E., Moonen, C. T. W., Storm, G., Kiessling, F., & Lammers, T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.07.007 · Cited by 260
Zhao, Y., Cao, J., Melamed, A., Worley, M., Gockley, A., Jones, D., Nia, H. T., Zhang, Y., Stylianopoulos, T., Kumar, A. S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1818357116 · Cited by 259
Liu, R., Xiao, W., Hu, C., Xie, R., & Gao, H. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.04.005 · Cited by 250
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.09.021 · Cited by 243
Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics
Abdalla, A. M. E., Xiao, L., Ullah, M. W., Yu, M., Ouyang, C., & Yang, G. (2018) · Theranostics · doi:10.7150/thno.21674 · Cited by 240
Nanoparticle-Mediated Remodeling of the Tumor Microenvironment to Enhance Immunotherapy
Musetti, S., & Huang, L. (2018) · ACS Nano · doi:10.1021/acsnano.8b05893 · Cited by 239
Lv, Y., Xu, C., Zhao, X., Lin, C., Yang, X., Xin, X., Zhang, L., Qin, C., Han, X., Yang, L., et al. (2018) · ACS Nano · doi:10.1021/acsnano.7b08051 · Cited by 235
Cancer nanomedicine: is targeting our target?
Lammers, T., Kiessling, F., Ashford, M., Hennink, W., Crommelin, D., & Storm, G. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.69 · Cited by 233
Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls
Nakamura, H., Jun, F., & Maeda, H. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.955011 · Cited by 232
Tumor Vasculature Targeted Photodynamic Therapy for Enhanced Delivery of Nanoparticles
Zhen, Z., Tang, W., Chuang, Y.-J., Todd, T., Zhang, W., Lin, X., Niu, G., Liu, G., Wang, L., Pan, Z., et al. (2014) · ACS Nano · doi:10.1021/nn501134q · Cited by 228
Huang, J., Frischer, J. S., Serur, A., Kadenhe, A., Yokoi, A., McCrudden, K. W., New, T., O'Toole, K., Zabski, S., Rudge, J. S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1432908100 · Cited by 227
Tumor microenvironment-responsive nanoparticles for cancer theragnostic applications
Uthaman, S., Huh, K. M., & Park, I.-K. (2018) · Biomaterials Research · doi:10.1186/s40824-018-0132-z · Cited by 227
Radiation therapy primes tumors for nanotherapeutic delivery via macrophage-mediated vascular bursts
Miller, M. A., Chandra, R., Cuccarese, M. F., Pfirschke, C., Engblom, C., Stapleton, S., Adhikary, U., Kohler, R. H., Mohan, J. F., Pittet, M. J., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal0225 · Cited by 225
Dual-Action Combination Therapy Enhances Angiogenesis while Reducing Tumor Growth and Spread
Wong, P.-P., Demircioglu, F., Ghazaly, E., Alrawashdeh, W., Stratford, M. R. L., Scudamore, C. L., Cereser, B., Crnogorac-Jurcevic, T., McDonald, S., Elia, G., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.10.015 · Cited by 223
Intestinal lymphatic vasculature: structure, mechanisms and functions
Bernier-Latmani, J., & Petrova, T. V. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.79 · Cited by 219
Synergistic enzymatic and bioorthogonal reactions for selective prodrug activation in living systems
Yao, Q., Lin, F., Fan, X., Wang, Y., Liu, Y., Liu, Z., Jiang, X., Chen, P. R., & Gao, Y. (2018) · Nature Communications · doi:10.1038/s41467-018-07490-6 · Cited by 219
TGF-β in T Cell Biology: Implications for Cancer Immunotherapy
Dahmani, A., & Delisle, J.-S. (2018) · Cancers · doi:10.3390/cancers10060194 · Cited by 214
Clemons, T. D., Singh, R., Sorolla, A., Chaudhari, N., Hubbard, A., & Iyer, K. S. (2018) · Langmuir · doi:10.1021/acs.langmuir.8b02946 · Cited by 211
Liu, J., Liang, H., Li, M., Luo, Z., Zhang, J., Guo, X., & Cai, K. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2017.12.003 · Cited by 210
Chemical Tumor-Targeting of Nanoparticles Based on Metabolic Glycoengineering and Click Chemistry
Lee, S., Koo, H., Na, J. H., Han, S. J., Min, H. S., Lee, S. J., Kim, S. H., Yun, S. H., Jeong, S. Y., Kwon, I. C., et al. (2014) · ACS Nano · doi:10.1021/nn406584y · Cited by 206
Self-citationHu, X.-X., He, P.-P., Qi, G.-B., Gao, Y.-J., Lin, Y.-X., Yang, C., Yang, P.-P., Hao, H., Wang, L., & Wang, H. (2017) · ACS Nano · doi:10.1021/acsnano.7b00781 · Cited by 205
“Targeting” nanoparticles: The constraints of physical laws and physical barriers
Florence, A. T. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.022 · Cited by 179
Chen, B., Pogue, B. W., Luna, J. M., Hardman, R. L., Hoopes, P. J., & Hasan, T. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1673 · Cited by 175
Hypoxia and hypoxia inducible factors in tumor metabolism
Zeng, W., Liu, P., Pan, W., Singh, S. R., & Wei, Y. (2015) · Cancer Letters · doi:10.1016/j.canlet.2014.01.032 · Cited by 170
Shim, M. K., Park, J., Yoon, H. Y., Lee, S., Um, W., Kim, J.-H., Kang, S.-W., Seo, J.-W., Hyun, S.-W., Park, J. H., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.11.032 · Cited by 169
Self-citationCuccarese, M. F., Dubach, J. M., Pfirschke, C., Engblom, C., Garris, C., Miller, M. A., Pittet, M. J., & Weissleder, R. (2017) · Nature Communications · doi:10.1038/ncomms14293 · Cited by 168
Tak, W. Y., Lin, S.-M., Wang, Y., Zheng, J., Vecchione, A., Park, S. Y., Chen, M. H., Wong, S., Xu, R., Peng, C.-Y., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2433 · Cited by 167
Does Nanomedicine Have a Delivery Problem?
Torrice, M. (2016) · ACS Central Science · doi:10.1021/acscentsci.6b00190 · Cited by 163
Luo, C., Sun, B., Wang, C., Zhang, X., Chen, Y., Chen, Q., Yu, H., Zhao, H., Sun, M., Li, Z., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.04.001 · Cited by 161
Doherty, G. J., Tempero, M. A., & Corrie, P. G. (2017) · Future Oncology · doi:10.2217/fon-2017-0338 · Cited by 158
Modulating the Tumor Microenvironment to Enhance Tumor Nanomedicine Delivery
Zhang, B., Hu, Y., & Pang, Z. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00952 · Cited by 152
Near infrared fluorescent peptide nanoparticles for enhancing esophageal cancer therapeutic efficacy
Fan, Z., Chang, Y., Cui, C., Sun, L., Wang, D. H., Pan, Z., & Zhang, M. (2018) · Nature Communications · doi:10.1038/s41467-018-04763-y · Cited by 151
Dual-targeted nanomedicines for enhanced tumor treatment
Zhu, Y., Feijén, J., & Zhong, Z. (2018) · Nano Today · doi:10.1016/j.nantod.2017.12.007 · Cited by 140
RGD peptide-based non-viral gene delivery vectors targeting integrin α v β 3 for cancer therapy
Fu, S., Xu, X., Ma, Y., Zhang, S., & Zhang, S. (2019) · Journal of drug targeting · doi:10.1080/1061186x.2018.1455841 · Cited by 139
Chen, J., Ouyang, J., Chen, Q., Deng, C., Meng, F., Zhang, J., Cheng, R., Lan, Q., & Zhong, Z. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b06879 · Cited by 124
Chemical tumor-targeting of nanoparticles based on metabolic glycoengineering and click chemistry
Jeong, S. Y., 김광명, 김선화, 이상민, 최귀원, 민현수, 권익찬, 이소진, 윤석현, 나진희, et al. (2014) · Cited by 122
Bioreducible Carboxymethyl Dextran Nanoparticles for Tumor‐Targeted Drug Delivery
Thambi, T., You, D. G., Han, H. S., Deepagan, V. G., Jeon, S. M., Suh, Y. D., Choi, K. Y., Kim, K., Kwon, I. C., Yi, G., et al. (2014) · Advanced Healthcare Materials · doi:10.1002/adhm.201300691 · Cited by 121
Self-citationCathepsin B‐Specific Metabolic Precursor for In Vivo Tumor‐Specific Fluorescence Imaging
Shim, M. K., Yoon, H. Y., Ryu, J. H., Koo, H., Lee, S., Park, J. H., Kim, J., Lee, S., Pomper, M. G., Kwon, I. C., et al. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201608504 · Cited by 115
Self-citationCancer targeted therapeutics: From molecules to drug delivery vehicles
Liu, D., & Auguste, D. T. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.041 · Cited by 114
Targeting VEGF pathway to normalize the vasculature: an emerging insight in cancer therapy
Wu, J., Tang, Y., & Liang, X. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s172042 · Cited by 114
Sun, C., Cao, Z., Zhang, X., Sun, R., Yu, C., & Yang, X. (2018) · Theranostics · doi:10.7150/thno.24015 · Cited by 113
Stromal barriers to nanomedicine penetration in the pancreatic tumor microenvironment
Tanaka, H. Y., & Kano, M. R. (2018) · Cancer Science · doi:10.1111/cas.13630 · Cited by 107
Tumor interstitial fluid pressure as an early-response marker for anticancer therapeutics
Ferretti, S., Allegrini, P. R., Becquet, M. M., & McSheehy, P. M. J. (2009) · Neoplasia · doi:10.1593/neo.09554 · Cited by 106
Chemotherapeutic drug delivery by tumoral extracellular matrix targeting
Raavé, R., van Kuppevelt, T. H., & Daamen, W. F. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.01.029 · Cited by 106
Ashton, J. R., Castle, K. D., Qi, Y. P., Kirsch, D. G., West, J. L., & Badea, C. T. (2018) · Theranostics · doi:10.7150/thno.22621 · Cited by 105
Size Dependent Kinetics of Gold Nanorods in EPR Mediated Tumor Delivery
Tong, X., Wang, Z., Sun, X., Song, J., Jacobson, O., Niu, G., Kiesewetter, D. O., & Chen, X. S. (2016) · Theranostics · doi:10.7150/thno.17098 · Cited by 103
Miller, M. A., Mikula, H., Luthria, G., Li, R., Kronister, S., Prytyskach, M., Köhler, R. H., Mitchison, T. J., & Weissleder, R. (2018) · ACS Nano · doi:10.1021/acsnano.8b07954 · Cited by 99
Abumanhal-Masarweh, H., Koren, L., Zinger, A., Yaari, Z. A., Krinsky, N., Kaneti, G., Dahan, N., Lupu-Haber, Y., Suss-Toby, E., Weiss‐Messer, E., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.01.004 · Cited by 97
Mimicking the physical cues of the ECM in angiogenic biomaterials
Crosby, C. O., & Zoldan, J. (2019) · Regenerative Biomaterials · doi:10.1093/rb/rbz003 · Cited by 88
Lee, S. J., Yook, S., Yhee, J. Y., Yoon, H. Y., Kim, M.-G., Ku, S. H., Kim, S. H., Park, J. H., Jeong, J. H., Kwon, I. C., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.032 · Cited by 87
Self-citationInfante, J. R., Korn, R. L., Rosen, L. S., LoRusso, P., Dychter, S. S., Zhu, J., Maneval, D. C., Jiang, P., Shepard, H. M., Frost, G., et al. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.327 · Cited by 83
Song, X., Wan, Z., Chen, T., Fu, Y. S., Jiang, K., Yi, X., Ke, H., Dong, J., Yang, L., Li, L., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.09.001 · Cited by 82
Targeting Cathepsin B for Cancer Therapies.
Ruan, H., Hao, S., Young, P. D., & Zhang, H. (2015) · PubMed · Cited by 80
Wang, Y., Liu, Z., Li, T., Chen, L., Lyu, J., Li, C., Lin, Y., Hao, N., Zhou, M., & Zhong, Z. (2019) · Theranostics · doi:10.7150/thno.30418 · Cited by 79
Xu, H., Ohulchanskyy, T. Y., Yakovliev, A., Ziniuk, R., Song, J., Liu, L., Qu, J., & Yuan, Z. (2019) · Theranostics · doi:10.7150/thno.31079 · Cited by 79
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date *
Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J., & Corrie, S. R. (2020) · doi:10.1201/9780429027819-7 · Cited by 74
Induced Phenotype Targeted Therapy: Radiation-Induced Apoptosis-Targeted Chemotherapy
Lee, B. S., Cho, Y. W., Kim, G. C., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju403 · Cited by 71
Caspase-3/-7-Specific Metabolic Precursor for Bioorthogonal Tracking of Tumor Apoptosis
Shim, M. K., Yoon, H. Y., Lee, S.-M., Jo, M. K., Park, J., Kim, J.-H., Jeong, S. Y., Kwon, I. C., & Kim, K. (2017) · Scientific Reports · doi:10.1038/s41598-017-16653-2 · Cited by 71
Self-citationA switchable NO-releasing nanomedicine for enhanced cancer therapy and inhibition of metastasis
Xu, Y., Ren, H., Liu, J., Wang, Y., Meng, Z., He, Z., Miao, W., Chen, G., & Li, X. (2019) · Nanoscale · doi:10.1039/c9nr00732f · Cited by 69
Controlled-release nanotherapeutics: State of translation
Tan, Y., Lao, L. L., Xiong, G. M., & Venkatraman, S. S. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.06.014 · Cited by 66
siRNA in ovarian cancer – Delivery strategies and targets for therapy
van den Brand, D., Mertens, V., Massuger, L. F. A. G., & Brock, R. E. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.012 · Cited by 60
Lee, S., Jung, S., Koo, H., Na, J. H., Yoon, H. Y., Shim, M. K., Park, J., Kim, J.-H., Lee, S., Pomper, M. G., et al. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.09.025 · Cited by 58
Self-citationLiposomes with cyclic RGD peptide motif triggers acute immune response in mice
Wang, X., Wang, H., Jiang, K., Zhang, Y., Zhan, C., Ying, M., Zhang, M., Lu, L., Wang, R., Wang, S., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.12.003 · Cited by 56
Doxorubicin/heparin composite nanoparticles for caspase-activated prodrug chemotherapy
Khaliq, N. U., Sandra, F. C., Park, D. Y., Lee, J., Oh, K. S., Kim, D., Byun, Y., Kim, I.-S., Kwon, I. C., Kim, S. Y., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.05.056 · Cited by 55
Self-citationLi, C., Yang, X., Zhang, M., Song, Y., Cheng, K., An, J., Zhang, X., Yang, X., Liu, B., & Zhao, Y. (2018) · Theranostics · doi:10.7150/thno.28241 · Cited by 54
Zhang, Q., Chen, J., Shen, J., Chen, S., Liang, K., Wang, H., & Chen, H. (2019) · Theranostics · doi:10.7150/thno.33472 · Cited by 53
Blanco, V., Chu, Z., Vallabhapurapu, S., Sulaiman, M. K., Kendler, A., Rixe, O., Warnick, R. E., Franco, R. S., & Qi, X. (2014) · Oncotarget · doi:10.18632/oncotarget.2214 · Cited by 52
Yoon, H. Y., Shin, M. L., Shim, M. K., Lee, S., Na, J. H., Koo, H., Lee, H., Kim, J.-H., Lee, K. Y., Kim, K., et al. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b01083 · Cited by 52
Self-citationAnti-angiogenesis or pro-angiogenesis for cancer treatment: focus on drug distribution.
Huang, D., Lan, H., Liu, F., Wang, S., Chen, X., Jin, K., & Mou, X. (2015) · Europe PMC (PubMed Central) · Cited by 50
Jain, S., Pathak, K., & Vaidya, A. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.05.077 · Cited by 50
Bioorthogonal Copper‐Free Click Chemistry In Vivo for Tumor‐Targeted Delivery of Nanoparticles
Koo, H., Lee, S., Na, J. H., Kim, S. H., Hahn, S. K., Choi, K., Kwon, I. C., Jeong, S. Y., & Kim, K. (2012) · Angewandte Chemie · doi:10.1002/ange.201206703 · Cited by 50
Self-citationIn-vitro and in-vivo difference in gene delivery by lithocholic acid-polyethyleneimine conjugate
Wang, J., Meng, F., Kim, B.-K., Ke, X., & Yeo, Y. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119296 · Cited by 49
MMP-2-Controlled Transforming Micelles for Heterogeneic Targeting and Programmable Cancer Therapy
Wang, Z., Wang, Y., Jia, X., Han, Q., Qian, Y., Li, Q., Xiang, J., Wang, Q., Hu, Z., & Wang, W. (2019) · Theranostics · doi:10.7150/thno.30915 · Cited by 48
Mao, C., Li, F., Zhao, Y., Debinski, W., & Ming, X. (2018) · Theranostics · doi:10.7150/thno.29580 · Cited by 47
Eino, D., Tsukada, Y., Naito, H., Kanemura, Y., Iba, T., Wakabayashi, T., Muramatsu, F., Kidoya, H., Arita, H., Kagawa, N., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0498 · Cited by 45
Sorace, A. G., Quarles, C. C., Whisenant, J. G., Hanker, A. B., McIntyre, J. O., Sanchez, V. M., & Yankeelov, T. E. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3680-8 · Cited by 44
Harnessing Tumor Microenvironment for Nanoparticle‐Mediated Radiotherapy
Zhu, S., Gu, Z., & Zhao, Y. (2018) · Advanced Therapeutics · doi:10.1002/adtp.201800050 · Cited by 44
Vasculogenensis, angiogenesis and special features of tumor blood vessels
Hiratsuka, S. (2010) · Frontiers in bioscience · doi:10.2741/3796 · Cited by 43
Kwak, G., Jo, S. D., Kim, D., Kim, H., Kim, M. G., Kim, K., Kwon, I. C., & Kim, S. H. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.08.015 · Cited by 41
Self-citationVascular-Promoting Therapy Reduced Tumor Growth and Progression by Improving Chemotherapy Efficacy
Bridges, E., & Harris, A. L. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.12.009 · Cited by 38
Yao, M., Ma, X., Zhang, X., Shi, L., Liu, T., Liang, X., Zhao, H., Li, X., Li, L., Gao, H., et al. (2019) · Theranostics · doi:10.7150/thno.29989 · Cited by 38
Ryu, J. H., Shin, M., Kim, S. A., et al. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.08.026 · Cited by 37
Self-citationRoode, L. E., Brighton, H. E., Bo, T., Perry, J. L., Parrott, M. C., Kersey, F. R., Luft, J. C., Bear, J. E., DeSimone, J. M., & Davis, I. J. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2015.12.382 · Cited by 34
Zhang, Q., Wang, N., Ma, M., Luo, Y., & Chen, H. (2019) · Advanced Therapeutics · doi:10.1002/adtp.201800152 · Cited by 34
Liang, Y., Peng, J., Li, N., Yu-Wai-Man, C., Wang, Q., Xu, Y., Wang, H., Tagalakis, A. D., & Du, Z. (2019) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2018.09.018 · Cited by 30
Penafuerte, C., Bautista-Lopez, N., Bouchentouf, M., Birman, E., Forner, K., & Galipeau, J. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003816 · Cited by 30
EGF-liposomes promote efficient EGFR targeting in xenograft colocarcinoma model
Zalba, S., Contreras, A. M., Merino, M., Navarro, I., de Ilarduya, C. T., Trocóniz, I. F., Koning, G., & Garrido, M. J. (2016) · Nanomedicine · doi:10.2217/nnm.15.208 · Cited by 26
Nanoparticles for Targeting Intratumoral Hypoxia: Exploiting a Potential Weakness of Glioblastoma
Aldea, M. D., Florian, I. A., Kacsó, G., Craciun, L., Boca, S., Şoriţău, O., & Florian, I. Ş. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1947-8 · Cited by 26
Hypoxia-Responsive Copolymer for siRNA Delivery
Perche, F., Biswas, S., Patel, N. R., & Torchilin, V. P. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-3148-4_12 · Cited by 25
Zhao, Y., Zhang, C., Gao, L., Yu, X., Lai, J., Lu, D., Bao, R., Wang, Y., Jia, B., Wang, F., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1655 · Cited by 25
Cathepsin B‐Specific Metabolic Precursor for In Vivo Tumor‐Specific Fluorescence Imaging
Shim, M. K., Yoon, H. Y., Ryu, J. H., Koo, H., Lee, S., Park, J. H., Kim, J., Lee, S., Pomper, M. G., Kwon, I. C., et al. (2016) · Angewandte Chemie · doi:10.1002/ange.201608504 · Cited by 19
Self-citationKamei, R., Tanaka, H. Y., Kawano, T., Morii, C., Tanaka, S., Nishihara, H., Iwata, C., & Kano, M. R. (2017) · Cancer Science · doi:10.1111/cas.13216 · Cited by 9
Infante, J. R., Korn, R. L., Rosen, L. S., LoRusso, P. M., Dychter, S. S., Zhu, J., Maneval, D. C., Jiang, P., Shepard, H. M., Frost, G. J., et al. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.438 · Cited by 9
Cited by
Design of liposomes as drug delivery system for therapeutic applications
Guimarães, D., Cavaco-Paulo, A., & Nogueira, E. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120571 · Cited by 1,196
Shi, Y., van der Meel, R., Chen, X., & Lammers, T. (2020) · Theranostics · doi:10.7150/thno.49577 · Cited by 868
Mendes, B. B., Conniot, J., Avital, A., Yao, D., Jiang, X., Zhou, X., Sharf-Pauker, N., Xiao, Y., Adir, O., Liang, H., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00104-y · Cited by 719
The Uniqueness of Albumin as a Carrier in Nanodrug Delivery
Spada, A., Emami, J., Tuszynski, J. A., & Lavasanifar, A. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00046 · Cited by 591
Design of therapeutic biomaterials to control inflammation
Tu, Z., Zhong, Y., Hu, H., Shao, D., Haag, R., Schirner, M., Lee, J., Sullenger, B., & Leong, K. W. (2022) · Nature Reviews Materials · doi:10.1038/s41578-022-00426-z · Cited by 513
Metadata
- Authors
- Park, J., Choi, Y., Chang, H., Um, W., Ryu, J. H., & Kwon, I. C.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2019
- Volume
- 9
- Issue
- 26
- Pages
- 8073-8090
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W2982701461
- Cited by
- 382
- References
- 150
- FWCI
- 10.87
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.